NA
MNPR icon

NewEdge Advisors’s Monopar Therapeutics MNPR Stock Holding History

NewEdge Advisors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Hold
600
– – ﹤0.01% 3105
2026
Q1 		$32.9K Hold
600
– – ﹤0.01% 3047
2025
Q4 		$39.2K Hold
600
– – ﹤0.01% 3030
2025
Q3 		$49K Hold
600
– – ﹤0.01% 2831
2025
Q2 		$21.5K Hold
600
– – ﹤0.01% 2933
2025
Q1 		$21.8K Hold
600
– – ﹤0.01% 2834
2024
Q4 		$13.2K Hold
600
– – ﹤0.01% 2938
2024
Q3 		$4.04K Hold
600
– – ﹤0.01% 3215
2024
Q2 		$2.19K Hold
600
– – ﹤0.01% 3318
2024
Q1 		$2.04K Buy
+600
New +$1.79K ﹤0.01% 3363

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

NewEdge Advisors's MNPR Position: Q2 2026 in Review

NewEdge Advisors held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 600 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3105.

NewEdge Advisors first reported a position in MNPR in Q1 2024 and has held it in 10 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • NewEdge Advisors held 600 shares of Monopar Therapeutics worth $55.6K as of Q2 2026.
  • NewEdge Advisors left its Monopar Therapeutics share count unchanged in Q2 2026.
  • Monopar Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3105 holding.
  • NewEdge Advisors first reported a position in Monopar Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.